- Home
- SLQT vs MLYS Comparison
SLQT vs MLYS Comparison
Compare SLQT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLQT | MLYS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.1M | 2.4B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SLQT | MLYS |
|---|---|---|
| Price | $1.41 | $30.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $3.88 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 1.2M | 1.2M |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,563,142,000.00 | N/A |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $7.65 | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $1.33 | $8.24 |
| 52 Week High | $6.86 | $47.65 |
Technical Indicators
Market Signals| Indicator | SLQT | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 35.15 |
| Support Level | $1.34 | $32.05 |
| Resistance Level | $1.72 | $33.63 |
| Average True Range (ATR) | 0.11 | 1.62 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 6.94 | 5.05 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.